BI Asset Management Fondsmaeglerselskab A S Sells 197,423 Shares of The Cooper Companies, Inc. $COO

BI Asset Management Fondsmaeglerselskab A S trimmed its position in The Cooper Companies, Inc. (NASDAQ:COO) by 95.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,550 shares of the medical device company’s stock after selling 197,423 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S’s holdings in Cooper Companies were worth $655,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Cooper Companies by 48.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,407 shares of the medical device company’s stock valued at $1,890,000 after acquiring an additional 7,363 shares in the last quarter. Vontobel Holding Ltd. lifted its position in shares of Cooper Companies by 32.5% in the 2nd quarter. Vontobel Holding Ltd. now owns 8,137 shares of the medical device company’s stock worth $579,000 after purchasing an additional 1,994 shares during the period. Callan Family Office LLC boosted its stake in shares of Cooper Companies by 12.7% during the 2nd quarter. Callan Family Office LLC now owns 4,365 shares of the medical device company’s stock valued at $311,000 after purchasing an additional 493 shares in the last quarter. Blue Trust Inc. grew its holdings in shares of Cooper Companies by 24.7% during the 2nd quarter. Blue Trust Inc. now owns 1,362 shares of the medical device company’s stock worth $97,000 after acquiring an additional 270 shares during the period. Finally, Aberdeen Group plc lifted its stake in shares of Cooper Companies by 11.0% in the 2nd quarter. Aberdeen Group plc now owns 131,342 shares of the medical device company’s stock valued at $9,346,000 after purchasing an additional 13,011 shares during the period. 24.39% of the stock is owned by institutional investors.

Cooper Companies Stock Down 0.8%

Shares of Cooper Companies stock opened at $81.48 on Tuesday. The company has a 50-day simple moving average of $81.45 and a two-hundred day simple moving average of $74.59. The stock has a market capitalization of $15.97 billion, a PE ratio of 43.34, a price-to-earnings-growth ratio of 2.34 and a beta of 1.03. The Cooper Companies, Inc. has a 52-week low of $61.78 and a 52-week high of $94.33. The company has a debt-to-equity ratio of 0.30, a quick ratio of 1.13 and a current ratio of 1.89.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings results on Thursday, December 4th. The medical device company reported $1.15 EPS for the quarter, beating analysts’ consensus estimates of $1.11 by $0.04. Cooper Companies had a net margin of 9.16% and a return on equity of 10.02%. The firm had revenue of $1.07 billion for the quarter, compared to analysts’ expectations of $1.06 billion. During the same quarter in the prior year, the company posted $1.04 earnings per share. The business’s revenue for the quarter was up 4.6% on a year-over-year basis. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. On average, analysts anticipate that The Cooper Companies, Inc. will post 3.98 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Holly R. Sheffield bought 1,230 shares of the stock in a transaction on Tuesday, December 16th. The shares were acquired at an average price of $80.75 per share, for a total transaction of $99,322.50. Following the purchase, the insider owned 39,052 shares of the company’s stock, valued at approximately $3,153,449. The trade was a 3.25% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Lawrence Erik Kurzius purchased 2,000 shares of Cooper Companies stock in a transaction dated Wednesday, December 17th. The stock was bought at an average price of $82.50 per share, with a total value of $165,000.00. Following the completion of the purchase, the director directly owned 7,777 shares of the company’s stock, valued at approximately $641,602.50. This trade represents a 34.62% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders have purchased 16,014 shares of company stock worth $1,304,416. 1.98% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

COO has been the topic of several recent research reports. Stifel Nicolaus set a $95.00 price target on Cooper Companies and gave the stock a “buy” rating in a research note on Friday, December 5th. KeyCorp reaffirmed a “sector weight” rating on shares of Cooper Companies in a research report on Friday, December 5th. Robert W. Baird increased their price target on shares of Cooper Companies from $85.00 to $98.00 and gave the stock an “outperform” rating in a research note on Friday, December 5th. Piper Sandler reissued an “overweight” rating and set a $94.00 price objective (up previously from $83.00) on shares of Cooper Companies in a research note on Friday, December 5th. Finally, William Blair raised shares of Cooper Companies to a “strong-buy” rating in a research note on Friday, January 30th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Cooper Companies currently has an average rating of “Moderate Buy” and a consensus price target of $90.77.

About Cooper Companies

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.